Carmoterol

Carmoterol
Clinical data
Other names	TA-2005; CHF-4226
Routes of; administration	Inhalation
ATC code	None;
Legal status
Legal status	Development terminated;
Identifiers
	IUPAC name 8-Hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1H-quinolin-2-one;
CAS Number	147568-66-9;
PubChem CID	63952;
ChemSpider	57545 ;
UNII	9810NUL4D1;
ChEMBL	ChEMBL1094785 ;
CompTox Dashboard (EPA)	DTXSID201046374 ;
Chemical and physical data
Formula	C21H24N2O4
Molar mass	368.433 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c3NC(=O)C=Cc23)cc1;
	InChI InChI=1S/C21H24N2O4/c1-13(11-14-3-5-15(27-2)6-4-14)22-12-19(25)16-7-9-18(24)21-17(16)8-10-20(26)23-21/h3-10,13,19,22,24-25H,11-12H2,1-2H3,(H,23,26)/t13-,19+/m1/s1; Key:IHOXNOQMRZISPV-YJYMSZOUSA-N;

Carmoterol (INN;^[1] development codes TA-2005 and CHF-4226) is a non-catechol^[2] experimental ultra-long-acting β adrenoreceptor agonist (ultra-LABA)^[2]^[3] that was in clinical trials before 2010 when it has been withdrawn from further development based on evidence that the compound does not possess a competitive profile.^[4]

Preliminary studies indicated duration of its effect exceeding 24 hours after inhalation of 3 μg.^[2] The pharmacologic profile of this medication included the fact its potency in isolated guinea pig trachea is greater than that of formoterol and salmeterol. It is over 100 times more selective for bronchial muscle than myocardial tissue.^[5]

References

^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 53" (PDF). WHO Drug Information. 19 (1): 74. 2005. Retrieved 25 March 2016.
^ ^a ^b ^c Mario C, Monica K (2008). "27. Bronchodilators: Beta2-Agonists and Anticholingercs". Clinical Asthma. 1600 John F. Kennedy Boulevard, Suite 1800, Philadelphia, PA 19103–2899: Mosby / Elsevier Health Sciences. ISBN 978-0-323-04289-5.{{cite book}}: CS1 maint: location (link)
^ Cazzola M, Calzetta L, Matera MG (May 2011). "β(2) -adrenoceptor agonists: current and future direction". British Journal of Pharmacology. 163 (1): 4–17. doi:10.1111/j.1476-5381.2011.01216.x. PMC 3085864. PMID 21232045.
^ "Chiesi: Annual Report 2010" (PDF). Chiesi Farmaceutici S.p.A. p. 20. Retrieved 27 March 2016.
^ Donohue JF (2006). "New Options in COPD Therapy". Medscape. Retrieved 27 March 2016.

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.

[1] "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 53" (PDF). WHO Drug Information. 19 (1): 74. 2005. Retrieved 25 March 2016.

[Castro-2] Mario C, Monica K (2008). "27. Bronchodilators: Beta2-Agonists and Anticholingercs". Clinical Asthma. 1600 John F. Kennedy Boulevard, Suite 1800, Philadelphia, PA 19103–2899: Mosby / Elsevier Health Sciences. ISBN 978-0-323-04289-5.{{cite book}}: CS1 maint: location (link)

[3] Cazzola M, Calzetta L, Matera MG (May 2011). "β(2) -adrenoceptor agonists: current and future direction". British Journal of Pharmacology. 163 (1): 4–17. doi:10.1111/j.1476-5381.2011.01216.x. PMC 3085864. PMID 21232045.

[4] "Chiesi: Annual Report 2010" (PDF). Chiesi Farmaceutici S.p.A. p. 20. Retrieved 27 March 2016.

[5] Donohue JF (2006). "New Options in COPD Therapy". Medscape. Retrieved 27 March 2016.

[1]

[2]

[3]

[4]

[5]